Viewpoint Capital Management LLC Has $2.03 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Viewpoint Capital Management LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 5.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 14,051 shares of the company’s stock after buying an additional 681 shares during the period. Johnson & Johnson makes up 1.1% of Viewpoint Capital Management LLC’s portfolio, making the stock its 26th largest holding. Viewpoint Capital Management LLC’s holdings in Johnson & Johnson were worth $2,032,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. AMF Tjanstepension AB boosted its holdings in Johnson & Johnson by 14.2% in the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock valued at $68,985,000 after purchasing an additional 52,997 shares during the period. Alpha Financial Partners LLC acquired a new stake in Johnson & Johnson during the third quarter worth approximately $209,000. Wealth Group Ltd. bought a new position in Johnson & Johnson during the 3rd quarter worth $213,000. Creative Planning lifted its position in shares of Johnson & Johnson by 4.3% during the 3rd quarter. Creative Planning now owns 988,403 shares of the company’s stock valued at $160,181,000 after acquiring an additional 41,082 shares during the period. Finally, Swedbank AB grew its holdings in shares of Johnson & Johnson by 5.3% during the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock worth $358,980,000 after purchasing an additional 111,570 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently weighed in on JNJ. Barclays upped their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 28th. Guggenheim increased their price target on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Wolfe Research began coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target on the stock. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Trading Down 0.7 %

Shares of JNJ stock opened at $156.20 on Friday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock has a market cap of $376.08 billion, a price-to-earnings ratio of 23.49, a PEG ratio of 2.46 and a beta of 0.52. The stock has a 50-day moving average of $147.87 and a 200-day moving average of $156.00.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same quarter last year, the business earned $2.29 EPS. The company’s revenue was up 5.3% compared to the same quarter last year. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.18%. Johnson & Johnson’s payout ratio is currently 74.59%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.